News

Metabolic health declining among the obese, despite improvements in BP and lipids


 

FROM THE JOURNAL OF THE AMERICAN HEART ASSOCIATION

References

The study was supported by the Department of Veterans Affairs, the National Institutes of Health, and the University of Alabama Diabetes Research Center.

Dr. Guo had no financial disclosures. Dr. Garvey disclosed relationships with multiple pharmaceutical companies.

msullivan@frontlinemedcom.com

Pages

Recommended Reading

Menopause and cardiovascular risk examined in type 1 diabetes
MDedge Endocrinology
Novel vaccine scores better hepatitis B seroprotection in type 2 diabetes
MDedge Endocrinology
FDA panel narrowly endorses empagliflozin’s cardiovascular mortality benefit
MDedge Endocrinology
In T1D, quality of life measures fall short
MDedge Endocrinology
What difference would an empagliflozin CVD indication make?
MDedge Endocrinology
High rates of early complications seen in youth with diabetes
MDedge Endocrinology
Statement warns of drugs causing or exacerbating heart failure
MDedge Endocrinology
Canagliflozin benefits cohort of type 1 diabetes patients
MDedge Endocrinology
Triple therapy helped type 1 patients improve glycemia
MDedge Endocrinology
Newer insulin glargine formula curbs nocturnal hypoglycemia
MDedge Endocrinology